Crowdonomics
WatchlistPortfolio
All companies
UpLyft™ logo

UpLyft™

Operating

DME Innovations, Inc

Healthcare · San Diego, CA · Founded 2016

Visit website

The 1st FDA-compliant self-transfer system for people between bed and wheelchair

Valuation cap ⓘ
$19.8M
As of Jan 2026 · from Reg CF Offering (2025) · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$3,223,599
Crowd $242K · Private $3.0M · 5 rounds since 2020
Latest share price
$0.7254
Section 4(a)(2) · Series Seed 2X Preferred Stock · Oct 2024 offering price

Financials

FY2018–FY2024 (no data for FY2020, FY2021, FY2022) · from SEC filings · hover any figure for its source
$0
−$147K
2018
$0
−$13K
2019
2020no data
2021no data
2022no data
$290K
−$979K
2023
$369K
−$1.6M
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018
FY2019 reviewed
FY2023 reviewed
FY2024 reviewed
Income statement
Revenue
$0
$0
$290,487
$368,709
Cost of goods sold
$0
$0
$297,989
$322,151
Gross margin
—
—
-3%
13%
Net income
-$147,205
-$13,294
-$978,602
-$1,622,213
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$908
$957
$99,562
$113,092
Accounts receivable
$0
$0
$220,878
$5,627
Total assets
$58,196
$76,901
$1,222,894
$1,013,515
Short-term debt
$18,643
$35,167
$1,440,341
$1,442,928
Long-term debt
$214,000
$227,000
$1,928,882
$1,991,433
Total liabilities
$232,643
$262,167
$3,369,223
$3,434,361
Other
Headcount
—
2
—
6

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Valuation caps on SAFE / convertible note rounds
$6.6M
Valuation cap
$19.8M
Valuation cap
Reg CF · Note · Aug 2020
Reg CF · Note · Oct 2025

Dashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth.

Share price over rounds

$0.7254$0.3627$0.5803
Jul 2022Oct 2024
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Fundraising history

Reg CF · Convertible Note · Oct 2025Closedvia StartEngine
Raised $59K / $618KInvestors 36Valuation cap $19.8M
Section 4(a)(2) · Series Seed 2X Preferred Stock · Oct 2024Closed
Raised $1.4M
Section 4(a)(2) · Series Seed Preferred Stock · Dec 2023Closed
Raised $802.9K
Section 4(a)(2) · Series Seed-3 Preferred Stock · Jul 2022Closed
Raised $767.5K
Reg CF · Convertible Note · Aug 2020Closedvia WeFunder
Raised $183.1K / $1.1MInvestors 189Valuation cap $6.6M

Team

8 people
Craig Howard Misrach
President, CEO, Principal Accounting Officer, Board Member

15+ years as medical device CEO, 3X venture creator with two M&A exits . MBA, University of Virginia; BS, Indiana; CPA

Craig Misrach
CEO, President, PAO, Board Member
Bria d’Amours
VP Marketing & Business Development

10+ years marketing and prior business ownership. MBA, USD

Todd Alexander Simson
VP Engineering, Board Member

25+ years in product design/manufacturing, 1 M&A exit. BS, MIT

Todd Simson
VP Engineering, Board Member
Aaron Metelko
Sales Director

25+ years in medical equipment sales. BS, Indiana

Rajit Malhotra
Executive Chairman of the Board

$1.8B equity created with 19 companies, 6 M&A exits. MBA, Northwestern; MPA/ID, Harvard

William Acuna
Director, Finance & Operations

10+ years leadership experience, U.S. Navy veteran. MBA, USD; MS-AAI, USD

Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Delinquent

Filed 0 of 6 annual reports (FY2020–FY2025)

Missing: 2020, 2021, 2022, 2023, 2024, 2025

189 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-UJan 27, 20260001818414-26-000004
    EDGAR
  • Form C/AJan 14, 20260001818414-26-000002
    EDGAR
  • Form COct 28, 20250001818414-25-000004
    EDGAR
  • Form C/ADec 8, 20200001670254-20-001120
    EDGAR
  • Form C/AAug 13, 20200001670254-20-000723
    EDGAR
  • Form CJul 20, 20200001670254-20-000631
    EDGAR
Source: ManualCIK 0001818414CAShare price $0.7254

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.